

[Streptokinase](#)

Essential medicine status

Section:

[12. Cardiovascular medicines](#) [12.5. Antithrombotic medicines](#) [12.5.2. Thrombolytic medicines](#)

ATC codes: [B01AD01](#)

Indication

Acute myocardial infarction ICD11 code: [BA41.Z](#)

INN

Streptokinase

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 1.5 million IU in vial powder for injection

EML status history

First added in 1991 ([TRS 825](#))

Changed in 1993 ([TRS 850](#))

Changed in 2003 ([TRS 920](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Streptokinase](#)

DrugBank

[Streptokinase](#)

Summary of evidence and Expert Committee recommendations

The Committee reviewed an application submitted by Aventis Behring, GmbH, Marburg Germany, to remove the 100000 IU dosage form of streptokinase from the Model List. The Committee noted that the recommended standard dosage for streptokinase's main indication, the treatment of acute myocardial infarction, is 1.5 million IU. The Committee recommended that the dosage form for streptokinase be changed to: powder for injection, 1.5 million IU in vial and that the note, "For use in rare or exceptional circumstances." be removed since its value in treating acute myocardial infarction is now well established and its use is no longer reserved for exceptional situations. The Committee recommended that the dosage form for streptokinase be changed to powder for injection, 1.5 million IU in vial and that the existing footnote, "For use in rare disorders or in exceptional circumstances." be removed.